People: Biohaven Pharmaceutical Holding Company Ltd (BHVN.N)
Dr. Declan Doogan, M.D., serves as Independent Chairman of the Board of Biohaven Pharmaceutical Holding Company Limited. Dr. Doogan has served as a director of our Company since its inception in September 2013. Dr. Doogan has served as the chief executive officer and director of Portage Biotech, Inc. (PTGEF: OTCBB) since June 2013, a director of Portage Pharmaceuticals Limited since July 2013, a director of Sosei Group Corporation from June 2007 to June 2018 and a director of Kleo Pharmaceuticals since August 2016. Dr. Doogan has over 30 years of industry experience in both major pharma and biotech. He was the Senior Vice-President and Head of Worldwide Development at Pfizer Inc., or Pfizer, and has held a number of executive positions in Pfizer in the United States, the United Kingdom and Japan. Since leaving Pfizer in 2007, he has been engaged in executive roles in small pharmaceutical companies. Dr. Doogan was chief medical officer and acting chief executive officer of Amarin Corporation plc (AMRN: NASDAQ). He has also been Chief Medical Officer for Prometheus Laboratories, a molecular diagnostics company in San Diego. Dr. Doogan holds a number of board appointments, principally in pharmaceutical companies, and has also held professorships at Harvard School of Public Health, Glasgow University Medical School and Kitasato University (Tokyo). Dr. Doogan received his medical degree from Glasgow University in 1975. He is a Fellow of the Royal College of Physicians and the Faculty of Pharmaceutical Medicine and holds a Doctorate of Science from the University of Kent in the UK. We believe that Dr. Doogan’s extensive operational experience in the pharmaceutical and biotech industries qualifies him to serve as a member of our Board.
|Total Annual Compensation, USD||621,360|
|Restricted Stock Award, USD||--|
|Long-Term Incentive Plans, USD||--|
|All Other, USD||85,000|
|Fiscal Year Total, USD||706,360|